Multi-cancer detection tests evoke conflicting reactions—the excitement at their promise is quickly dampened by concerns over the uncertainty of their clinical benefit, very low sensitivity for detecting stage 1 cancers, and the risks that come from subsequent workups.
Cedars-Sinai performed the first robot-assisted microsurgical head-and-neck cancer reconstructive surgery in the United States after the robot device received FDA approval for the procedure.
